Wall Street brokerages expect Illumina, Inc. (NASDAQ:ILMN) to announce earnings per share of $1.40 for the current quarter, according to Zacks. Six analysts have made estimates for Illumina’s earnings. The highest EPS estimate is $1.51 and the lowest is $1.31. Illumina reported earnings per share of $1.43 during the same quarter last year, which would suggest a negative year over year growth rate of 2.1%. The business is expected to issue its next quarterly earnings results on Monday, July 29th.
On average, analysts expect that Illumina will report full-year earnings of $6.68 per share for the current financial year, with EPS estimates ranging from $6.61 to $6.72. For the next year, analysts expect that the business will report earnings of $7.66 per share, with EPS estimates ranging from $7.45 to $8.20. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Illumina.
Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 25th. The life sciences company reported $1.60 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.34 by $0.26. The firm had revenue of $846.00 million for the quarter, compared to analysts’ expectations of $838.70 million. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The company’s quarterly revenue was up 8.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.45 earnings per share.
ILMN has been the topic of a number of research analyst reports. BidaskClub raised shares of Illumina from a “sell” rating to a “hold” rating in a report on Wednesday, February 13th. Deutsche Bank lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 price target on the stock. in a report on Friday, January 25th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $355.00 price target on the stock in a report on Tuesday, April 2nd. Bank of America reissued a “buy” rating and issued a $355.00 price target on shares of Illumina in a report on Wednesday, January 30th. Finally, Leerink Swann raised shares of Illumina to an “outperform” rating and decreased their price target for the stock from $380.00 to $365.00 in a report on Wednesday, January 30th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $353.58.
Illumina stock traded up $3.45 during midday trading on Friday, reaching $310.03. 30,286 shares of the stock were exchanged, compared to its average volume of 988,027. The company has a current ratio of 3.66, a quick ratio of 3.33 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $45.34 billion, a PE ratio of 54.18, a price-to-earnings-growth ratio of 2.09 and a beta of 1.15. Illumina has a 52 week low of $261.61 and a 52 week high of $372.61.
In related news, Director Jay T. Flatley sold 3,300 shares of the stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $321.96, for a total transaction of $1,062,468.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Omead Ostadan sold 1,260 shares of the stock in a transaction on Friday, February 15th. The shares were sold at an average price of $294.62, for a total transaction of $371,221.20. Following the transaction, the senior vice president now directly owns 29,534 shares in the company, valued at approximately $8,701,307.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 41,589 shares of company stock worth $12,964,996. 0.38% of the stock is owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the stock. Massmutual Trust Co. FSB ADV lifted its position in shares of Illumina by 83.0% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 39 shares during the period. First Manhattan Co. boosted its holdings in shares of Illumina by 18.8% in the first quarter. First Manhattan Co. now owns 3,464 shares of the life sciences company’s stock worth $1,076,000 after buying an additional 547 shares during the last quarter. Sapphire Star Partners LP purchased a new position in shares of Illumina in the fourth quarter worth approximately $360,000. Machina Capital S.A.S. purchased a new position in shares of Illumina in the fourth quarter worth approximately $1,099,000. Finally, Ardevora Asset Management LLP boosted its holdings in shares of Illumina by 14.2% in the first quarter. Ardevora Asset Management LLP now owns 101,212 shares of the life sciences company’s stock worth $31,446,000 after buying an additional 12,600 shares during the last quarter. 90.80% of the stock is currently owned by institutional investors.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Further Reading: What is a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.